Regeneron Pharmaceuticals Inc. (REGN): Price and Financial Metrics

Regeneron Pharmaceuticals Inc. (REGN): $739.95

8.78 (+1.20%)

POWR Rating

Component Grades

Momentum

B

Stability

C

Sentiment

Quality

B

Add REGN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#6 of 380

in industry

REGN Price/Volume Stats

Current price $739.95 52-week high $837.55
Prev. close $731.17 52-week low $538.01
Day low $724.12 Volume 527,300
Day high $740.18 Avg. volume 598,368
50-day MA $783.70 Dividend yield N/A
200-day MA $738.18 Market Cap 80.90B

REGN Stock Price Chart Interactive Chart >

REGN POWR Grades

  • REGN scores best on the Value dimension, with a Value rank ahead of 92.2% of US stocks.
  • REGN's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • REGN's current lowest rank is in the Stability metric (where it is better than 60.64% of US stocks).

REGN Stock Summary

  • With a market capitalization of $80,900,341,300, REGENERON PHARMACEUTICALS INC has a greater market value than 97.53% of US stocks.
  • As for revenue growth, note that REGN's revenue has grown -25.07% over the past 12 months; that beats the revenue growth of only 9.19% of US companies in our set.
  • The volatility of REGENERON PHARMACEUTICALS INC's share price is greater than that of merely 12.07% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to REGN, based on their financial statements, market capitalization, and price volatility, are VRTX, LRCX, CDNS, AMAT, and KLAC.
  • Visit REGN's SEC page to see the company's official filings. To visit the company's web site, go to www.regeneron.com.

REGN Valuation Summary

  • In comparison to the median Healthcare stock, REGN's price/sales ratio is 29.41% higher, now standing at 6.6.
  • Over the past 243 months, REGN's price/earnings ratio has gone up 24.4.

Below are key valuation metrics over time for REGN.

Stock Date P/S P/B P/E EV/EBIT
REGN 2023-05-23 6.6 3.5 19.6 17.1
REGN 2023-05-22 6.7 3.5 19.7 17.2
REGN 2023-05-19 6.7 3.5 19.9 17.4
REGN 2023-05-18 6.6 3.5 19.6 17.1
REGN 2023-05-17 6.6 3.5 19.7 17.2
REGN 2023-05-16 6.6 3.5 19.5 17.0

REGN Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 228.92%.
  • The 4 year net cashflow from operations growth rate now stands at 23.95%.
  • Its 5 year price growth rate is now at 32.25%.
REGN's revenue has moved up $4,193,100,000 over the prior 34 months.

The table below shows REGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 12,172.9 5,014.9 4,338.4
2022-09-30 13,710.2 5,667.5 5,370.3
2022-06-30 14,226.8 8,452.2 5,686.8
2022-03-31 16,508.1 8,514.5 7,933.6
2021-12-31 16,071.7 7,081.3 8,075.3
2021-09-30 13,542.9 5,939.8 6,995.5

REGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • REGN has a Quality Grade of B, ranking ahead of 86.94% of graded US stocks.
  • REGN's asset turnover comes in at 0.683 -- ranking 43rd of 681 Pharmaceutical Products stocks.
  • JAZZ, AGLE, and VERU are the stocks whose asset turnover ratios are most correlated with REGN.

The table below shows REGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.683 0.868 0.456
2021-03-31 0.562 0.868 0.315
2020-12-31 0.536 0.868 0.292
2020-09-30 0.540 0.880 0.283
2020-06-30 0.543 0.882 0.282
2020-03-31 0.553 0.897 0.221

REGN Price Target

For more insight on analysts targets of REGN, see our REGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $683.25 Average Broker Recommendation 1.52 (Moderate Buy)

Regeneron Pharmaceuticals Inc. (REGN) Company Bio


Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester CountyNew York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors. (Wikipedia:Source)


REGN Latest News Stream


Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream


Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 4th Annual Oncology Innovation Summit (Transcript)

Regeneron Pharmaceuticals, Inc. (REGN)

TD Cowen 4th Annual Oncology Innovation Summit

May 30, 2023 12:30 PM ET

Company Participants

Izzy Lowy - SVP, Solid Organ Oncology Development

Andres Sirulnik - SVP, Translational & Clinical Sciences, Hematology

Ryan Crowe - VP, IR

Conference Call Participants

Tyler Van Buren - TD Cowen

Presentation

Tyler Van Buren

All right. We'll give it a couple of seconds for everyone to join. Okay. So with that, welcome, everyone, again, to the TD Cowen's 4th Annual Oncology Innovation Summit Highlights for ASCO and EHA. My name is Tyler Van Buren, Senior Biotech Analyst here at TD Cowen. For our next session, we're very ...

SA Transcripts on Seeking Alpha | May 30, 2023

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.

Yahoo | May 26, 2023

Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma

71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also observed across prespecified subgroups, including patients with high disease burden and aggressive disease Data from this trial to form the basis of planned regulatory submissions, starting with the FDA in 2023 TARRYTOWN, N.Y., May 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: R

Yahoo | May 25, 2023

Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations

Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar settings – per trial results to be presented in an oral session at ASCO Clinically meaningful responses observed in post hoc analyses of populations of interest, including patients with poor prognosis factors, prior anti-PD-1 therapy in the adjuvant setting and varying tumor PD-L1 expression levels Pivot

Yahoo | May 25, 2023

14 Best Biotech Stocks To Buy According To Hedge Funds

In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]

Yahoo | May 25, 2023

Read More 'REGN' Stories Here

REGN Price Returns

1-mo -2.91%
3-mo -5.18%
6-mo -1.01%
1-year 17.39%
3-year 23.63%
5-year 137.28%
YTD 2.56%
2022 14.25%
2021 30.72%
2020 28.66%
2019 0.53%
2018 -0.65%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!